ANPG, TotalEnergies invest $850 million in Phase 3 of Angolan Block 17

June 13, 2022
The ANPG, TotalEnergies and their partners have made a final investment decision of $850 million for the launch of the CLOV Phase 3 development.

Offshore staff

LUANDA — The National Agency for Oil, Gas and Biofuels (ANPG), TotalEnergies and its Block 17 partners (Equinor, Exxon Mobil, bp and Sonangol P&P) announced the final investment decision of US$850 million for the launch of the CLOV Phase 3 development offshore Block 17, which is 150 km from the Angolan coast, according to a recent ANPG news release.

It is an extension of the subsea production network and its interconnection to the CLOV FPSO to develop additional production of existing fields, which can reach a peak of 30,000 bbl/d to sustain production of the CLOV Field, which began in 2014.

This development is the first to benefit from the standardization of subsea equipment in Block 17, through engineering and contractual structures, which represent a significant cost reduction and benefit the portfolio of short-cycle development projects in the different fields of the block.

Chairman of the ANPG board of directors, Paulino Jerónimo, said this project "opens a new cycle in Block 17, in which the standardization of subsea equipment for future developments will bring a cost reduction in the order of 20% and may generate opportunities to maintain production in other FPSOs."

It is recalled that the CLOV Phase 3 development project comprises the extension of the submarine infrastructure and five new wells at water depths between 1,100 m and 1,400 m, with a production start planned for 2024. It involves 2 million hours of work, of which 1.5 million are being carried out in Angola, mainly in Lobito (Sonamet shipyard) and in Luanda (Sonils' logistics base).

TotalEnergies operates Block 17 with a 38% stake, with shares in Equinor (22.16%), Exxon Mobil (19%), BP Exploration Angola Ltd. (15.84%) and Sonangol P&P (5%). Block 17 has four FPSOs in operation – Sunflower, Dahlia, Pazflor and CLOV.